Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

Victoria L Bridgeman,1 Peter B Vermeulen,1,2 Shane Foo,1 Agnes Bilecz,3 Frances Daley,4 Eleftherios Kostaras,1 Mark R Nathan,1 Elaine Wan,1,3 Sophia Frentzas,1,3 Thomas Schweiger,1 Balazs Hegedus,7,8 Konrad Hoetzenecker,4 Ferenc Renyi-Vamos,9 Elizabeth A Kuczynski,10 Naveen S Vasudev,11,11 James Larkin,5 Martin Gore,10 Harold F Dvorak,12 Sandor Paku,13,13 Robert S Kerbel,10,15 Balazs Dome5,16,17* and Andrew R Reynolds11*

Abstract

Anti-angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti-angiogenic therapies are poorly understood. Importantly, rather than utilizing angiogenesis, some metastases may instead incorporate pre-existing vessels from surrounding tissue (vessel co-option). As anti-angiogenic therapies were designed to target only new blood vessel growth, vessel co-option has been proposed as a mechanism that could drive resistance to anti-angiogenic therapy. However, vessel co-option has not been extensively studied in lung metastases, and its potential to mediate resistance to anti-angiogenic therapy in lung metastases is not established. Here, we examined the mechanism of tumour vascularization in 164 human lung metastasis specimens (composed of breast, colorectal and renal cancer lung metastasis cases). We identified four distinct histopathological growth patterns (HGPs) of lung metastasis (alveolar, interstitial, perivascular cuffing, and pushing), each of which vasculatized via a different mechanism. In the alveolar HGP, cancer cells invaded the alveolar air spaces, facilitating the co-option of alveolar capillaries. In the interstitial HGP, cancer cells invaded the alveolar walls to co-opt alveolar capillaries. In the perivascular cuffing HGP, cancer cells grew by co-opting larger vessels of the lung. Only in the pushing HGP did the tumours vascularize by angiogenesis. Importantly, vessel co-option occurred with high frequency, being present in >80% of the cases examined. Moreover, we provide evidence that vessel co-option mediates resistance to the anti-angiogenic drug sunitinib in preclinical lung metastasis models. Assuming that our interpretation of the data is correct, we conclude that vessel co-option in lung metastases occurs through at least three distinct mechanisms, that vessel co-option occurs frequently in lung metastases, and that vessel co-option could mediate resistance to anti-angiogenic therapy in lung metastases. Novel therapies designed to target both angiogenesis and vessel co-option are therefore warranted.
Introduction

Although the progression of metastases is considered to require new blood vessel growth (angiogenesis), anti-angiogenic drugs have shown limited efficacy in patients with metastatic disease. Metastases can be either unresponsive to anti-angiogenic therapy from the outset (intrinsic resistance) or can develop resistance after an initial period of response (acquired resistance). The mechanisms that mediate this resistance are still poorly understood [1–5].

However, rather than inducing angiogenesis, it now emerges that some tumours can instead incorporate pre-existing blood vessels from the surrounding normal tissue, a process known as vessel co-option or vascular co-option [5–7]. For example, seminal studies on non-small-cell lung cancer (NSCLC) demonstrated that some NSCLCs utilize vessel co-option instead of angiogenesis [8–12]. In this ‘non-angiogenic’ subtype of NSCLC, the cancer cells grow only within the alveolar air spaces. This permits intact alveolar walls to be incorporated into the tumour, allowing the tumour to co-opt the alveolar capillaries that are contained within those alveolar walls [8–12]. A similar presentation has been reported in some cases of human lung metastasis [13–15]. In addition, we recently examined the mechanism of tumour vascularization in several preclinical models of lung metastasis. In all models examined, the lung metastases co-opted alveolar capillaries by occupying the alveolar air spaces [16].

Given that conventional anti-angiogenic drugs were designed only to inhibit angiogenesis, the presence of vessel co-option in tumours may help to explain the limited efficacy of conventional anti-angiogenic therapies [7]. In support of this, vessel co-option has now been implicated as a mechanism of resistance to anti-angiogenic drugs in glioblastoma [17–19], hepatocellular carcinoma [20], lymph node metastases [21], liver metastases [22], and brain metastases [23,24]. However, a role for vessel co-option in driving therapy resistance in lung metastases has not been reported.

In the current article, we describe three distinct mechanisms of vessel co-option in human lung metastases. We also quantify the incidence of vessel co-option across a large series of human lung metastasis cases. Finally, we utilize preclinical lung metastasis models to investigate whether vessel co-option can mediate resistance to anti-angiogenic therapy.

Materials and methods

Human samples

Formalin-fixed paraffin-embedded samples of human lung metastases were retrieved from archives at the St Augustinus Hospital (Antwerp, Belgium), the Medical University of Vienna (Vienna, Austria), and the National Koranyi Institute of Pulmonology (Budapest, Hungary). This initial series consisted of 193 lesions from 181 patients. Haematoxylin and eosin (H&E)-stained sections were prepared from all cases for an initial histopathological assessment. Twenty-nine lesions were then excluded because they were unsuitable (supplementary material, Figures S1–S3). The final series analysed consisted of 164 lesions from 158 patients (46 breast cancer metastases from 46 patients, 57 colorectal cancer metastases from 53 patients, and 61 renal cancer metastases from 59 patients). For patient details, see supplementary material, Tables S1–S3.

Ethical approval was obtained from the Research Ethics Committee of the GZA Hospitals St Augustinus, the Ethics Committee of the Medical University of Vienna, and the National Scientific and Ethics Committee of Hungary.

Staining of tissue sections, histopathological analysis, and preclinical models

Details of the procedures that were used for tissue staining, scoring of histopathological growth patterns, scoring of breast cancer subtypes (which were determined as per published guidelines [25–27]) and in vivo models can be found in supplementary material, Supplementary materials and methods. The Institute of Cancer Research Animal Ethics Committee granted approval for animal work, and procedures were performed in accordance with the UK Home Office regulations.

Statistical analysis

Statistical analysis was performed with a two-tailed Fisher’s exact test or a two-tailed Student’s t-test. P-values of <0.05 were considered to be significant.

Results

Human lung metastases present with distinct growth patterns that are associated with different vascularization mechanisms

To investigate the mechanisms of tumour vascularization in human lung metastases, we performed a
Co-option of alveolar capillaries in the alveolar HGP

In previous studies, incorporation of intact alveolar walls into lung metastases has been cited as evidence that these tumours co-opt pre-existing alveolar capillaries [13,14,16]. In order to robustly identify the presence of alveolar walls in human tissue specimens, we performed staining for the established pneumocyte marker cytokeratin (CK) 7 [28]. In normal human lung, CK7 staining demonstrated a network of CK7-positive alveolar walls separated by intervening alveolar air spaces (Figure 1A). This ‘honeycomb’ morphology is characteristic of normal human lung parenchyma. Staining for a second established pneumocyte marker, thyroid transcription factor 1 [29], gave similar results.

We then performed staining for pneumocytes in samples of human breast cancer lung metastases. This approach clearly demonstrated two of the growth patterns of human lung metastases: the alveolar HGP and the pushing HGP. In the alveolar HGP, the cancer cells at the periphery of the metastasis entered the alveolar air spaces of the lung, which led to the incorporation of intact alveolar walls into the tumour (Figure 1C). In contrast, in the pushing HGP, the cancer cells did not enter the alveolar air spaces. Instead, the alveolar walls at the periphery of the metastases were pushed away by the tumour (Figure 1E).

Additionally, we examined blood vessels by staining for the vascular endothelial marker CD31. In normal human lung, a honeycomb network of CD31-positive alveolar walls, separated by intervening alveolar air spaces, was observed (Figure 1B). Importantly, in metastases with an alveolar HGP, the tumour vessel architecture closely resembled the vascular architecture of the normal lung (Figure 1D), suggesting that these tumours do co-opt pre-existing alveolar capillaries by growing within the alveolar air spaces [8–10,13]. However, in sharp contrast, pushing HGP metastases contained abnormal and chaotically organized vessels (Figure 1F), which is typical of vessels generated by tumour angiogenesis [8–10,13]. Equivalent growth patterns were observed in both colorectal cancer and renal cancer lung metastases (supplementary material, Figures S4 and S5).

Our interpretation of these data is that, whereas alveolar HGP lung metastases utilize vessel co-option to obtain a vascular supply, pushing HGP lung metastases utilize angiogenesis.

To further characterize the mechanism of vessel co-option, lung metastases were co-stained for CK7 and CD31. In normal lung, this staining demonstrated the architecture of the normal alveolar walls, which are lined by CK7-positive pneumocytes and contain CD31-positive alveolar capillaries (Figure 2A). At the tumour–lung interface of alveolar HGP metastases, cancer cells invaded into the air spaces, facilitating the co-option of CD31/CK7-positive alveolar walls into the metastases (Figure 2B). Just behind the tumour–lung interface, the alveolar air spaces were fully occupied by cancer cells, but the co-opted CD31/CK7-positive alveolar walls remained intact (Figure 2C; supplementary material, Figure S6A–C). Co-opted alveolar capillaries often contained erythrocytes, confirming that the co-opted blood vessels were perfused (supplementary material, Figure S6D, E).

Moving towards the centre of the metastases, CD31-positive alveolar capillaries could be found that were now only partially associated with CK7-positive pneumocytes, suggesting that alveolar epithelium is gradually lost from co-opted alveolar capillaries (Figure 2D). To further corroborate this, alveolar HGP lung metastases stained for CK7 were viewed at low power. Whereas pneumocyte-rich alveolar walls were incorporated at the periphery of the metastases, a gradual loss of pneumocytes towards the centre of the metastases was evident (supplementary material, Figure S7). Our interpretation of these data is that cancer cells first co-opt alveolar walls by invading the alveolar air spaces and that, subsequently, pneumocytes are gradually lost from these co-opted alveolar walls. However, after loss of these pneumocytes, the co-opted alveolar capillaries are retained by the tumour. In contrast, in pushing HGP lung metastases, we found no incorporation of alveolar walls into the tumour, suggesting that pushing HGP lung metastases do not co-opt alveolar capillaries (Figure 2E, F).

Co-option of alveolar capillaries in the interstitial HGP

In this study, we also observed a second growth pattern via which human lung metastases may co-opt alveolar capillaries. In the interstitial HGP, cancer cells were seen to co-opt alveolar capillaries by growing within the alveolar walls of the lung. The interstitial HGP is illustrated here with a case of renal cancer lung metastasis (Figure 3). Co-staining for carbonic anhydrase 9 (CAIX), to detect renal cancer cells, and CK7, to detect pneumocytes, demonstrated the infiltration of cancer cells into the normal alveolar walls at the tumour–lung interface (Figure 3A). To verify that this mode of infiltrative growth permits co-option of alveolar capillaries, co-staining for CAIX and CD31 was utilized. Close inspection of the alveolar walls at the tumour–lung interface demonstrated thin columns of cancer cells invading through the alveolar interstitium between the pre-existing alveolar capillaries (Figure 3B). Our interpretation of these data is that cancer cells can also invade through the alveolar walls to facilitate the co-option of alveolar capillaries.
Just behind the tumour–lung interface, CAIX-positive cancer cells completely filled the alveolar walls, but the intervening alveolar air spaces were preserved (Figure 3C). Importantly, these cancer-filled alveolar walls contained an abundance of co-opted alveolar capillaries (Figure 3D). Deeper into the metastasis, expansion of the cancer cell population resulted in significant broadening of the alveolar walls, but the intervening alveolar air spaces were mostly still preserved (Figure 3E). Some invasion of cancer cells into the alveolar air spaces was, however, also detected in the centre of the metastasis (Figure 3E). Within the metastasis, we often observed blood vessels that were closely associated with the abluminal side of the air spaces (Figure 3F). If our interpretation of the data is correct, the close association of these particular vessels with pneumocytes, deep within the metastasis, indicates that these are co-opted alveolar capillaries rather than newly formed vessels. However, we cannot completely rule out the possibility that angiogenesis also occurs in this growth pattern, especially in the centre of the metastasis. We named this growth pattern the interstitial HGP because of the propensity for cancer cells to grow within the alveolar interstitium, and to be consistent with a previous report of a similar growth pattern [14].

Co-option of large blood vessels in the perivascular cuffing HGP

Thus far, we have described two mechanisms via which cancer cells co-opt alveolar capillaries. However, the lungs also contain larger vessels (i.e. arteries and veins) that are distinct from alveolar capillaries because of their larger calibre and because they are surrounded by
Figure 2. Vessel co-option occurs in the alveolar growth pattern of human lung metastases. (A–D) Immunofluorescence co-staining for CD31 (red) and CK7 (green) in a case of human breast cancer lung metastasis that presented with an alveolar HGP. (A) In areas of tumour-free normal lung parenchyma, the alveolar walls are composed of CD31-positive alveolar capillaries (red) that are sheathed by CK7-positive pneumocytes (green). (B) At the tumour–lung interface, cancer cells (asterisks) invade an alveolar air space. Arrowheads indicate two CD31-positive alveolar macrophages in the alveolar air space that also reacted with the CD31 antibody. (C) Behind the tumour–lung interface, cancer cells (asterisks) completely fill the alveolar air spaces, preserving the alveolar walls and the associated alveolar capillaries. (D) Towards the centre of the metastatic lesion, co-opted alveolar capillaries can be found that are only partially coated by pneumocytes. Arrows indicate pneumocytes that are still associated with co-opted alveolar capillaries. Arrowheads indicate autofluorescent erythrocytes in the lumen of co-opted alveolar capillaries. (E, F) Immunofluorescence co-staining for CD31 (red) and CK7 (green) in a sample of human renal cancer lung metastasis with a pushing HGP. At the tumour–lung interface, cancer cells push the alveolar walls away (E). No incorporation of alveolar walls was observed either at the tumour–lung interface (E) or deeper into the metastasis (F). Alveolar air space: air. Normal lung: lung. Scale bar: 25 μm.
Vessel co-option in lung metastases

Figure 3. Vessel co-option occurs in the interstitial growth pattern of human lung metastases. Immunohistochemical analysis of a renal cancer lung metastasis with an interstitial HGP, illustrating growth of cancer cells within the alveolar walls. Staining for CAIX (brown) was used to detect cancer cells, in combination with either CK7 staining (green) to detect pneumocytes (A, C, E) or CD31 staining (green) to detect blood vessels (B, D, F). (A) Tumour–lung interface: alveolar walls filled with cancer cells are present at the top of the image (asterisks), whereas tumour-free alveolar walls of the normal lung are present below (diamond symbols). (B) High-power view of an alveolar wall (delineated with a dashed line). Asterisks indicate cancer cells that are infiltrating around pre-existing alveolar capillaries. (C, D) The area just behind the tumour–lung interface: the alveolar walls are now completely filled with cancer cells. The intervening alveolar air spaces remain intact. (E, F) The centre of the metastasis. In (E), asterisks indicate cancer cells that are filling the expanded alveolar walls, while the intervening alveolar air spaces remain intact. The arrow indicates an alveolar air space that has become partially filled with cancer cells. In (F), arrowheads indicate blood vessels that are closely associated with the abluminal side of an alveolar air space. Alveolar air space: air. Scale bars: 100 μm (A, C, D, E, F) and 50 μm (B).

Frequency of the different growth patterns in human lung metastases

To evaluate the frequencies of the alveolar, interstitial, perivascular cuffing and pushing HGPs in human lung metastases, all 164 cases were scored for their HGP (Figure 4A–C). It is of note that some lesions presented with more than one growth pattern. Therefore, the percentage of the tumour–lung interface adopting each growth pattern was scored in intervals of 5%.

To formally analyse the prevalence of vessel co-option across the different tumour types, growth patterns that utilize vessel co-option (alveolar, interstitial, and perivascular cuffing) were pooled together, and their incidence was compared with the incidence of the angiogenic pushing growth pattern. Vessel co-opting growth patterns were present to some extent (≥5% of the tumour–lung interface) in 91.3% of breast, 98.2% of colorectal and 62.3% of renal cancer metastases.
Moreover, vessel co-opting growth patterns were dominant (≥75% of the tumour–lung interface) in 71.7% of breast, 78.9% of colorectal and 37.7% of renal cancer metastases. Vessel co-opting growth patterns were more common in breast cancer than in renal cancer ($p = 0.0008$, Fisher’s exact test), and in colorectal cancer than in renal cancer ($p < 0.0001$, Fisher’s exact test).

Breast cancer metastases were also characterized for intrinsic molecular subtype: luminal A, luminal B (HER2-negative), luminal B (HER2-positive), HER2-positive (non-luminal), and triple-negative. Vessel co-opting growth patterns were present across all subtypes (supplementary material, Figure S9). However, vessel co-option was less prevalent in triple-negative tumours than in other subtypes ($p = 0.022$, Fisher’s exact test).

Limited efficacy of sunitinib in lung metastasis models as compared with subcutaneously implanted tumours

Conventional anti-angiogenic therapies were designed to inhibit new blood vessel growth, but were not designed to target vessel co-option. To investigate whether vessel co-option could mediate resistance to anti-angiogenic therapy in lung metastases, we utilized three preclinical syngeneic tumour models corresponding to the three types of human cancer studied above.

Figure 4. Frequency of the different HGPs in lung metastases of human breast, colorectal and renal cancer. Lung metastases of human breast cancer (A), human colorectal cancer (B) and human renal cancer (C) were scored for their growth pattern. Each bar represents an individual case of metastasis showing the percentage of the tumour–lung interface scored as alveolar, interstitial, perivascular cuffing or pushing HGP. $n = 46$ breast cancer lung metastases (A), $n = 57$ colorectal cancer lung metastases (B), and $n = 61$ renal cancer lung metastases (C).
The 4T1 cell line was used to model breast cancer, and the C26 and RENCA cell lines were used to model colorectal and renal cancer, respectively. To examine the response to anti-angiogenic therapy, we utilized the potent anti-angiogenic tyrosine kinase inhibitor sunitinib.

As the growth of subcutaneously implanted tumours is known to be angiogenesis-dependent, we first assessed sunitinib activity against subcutaneously implanted 4T1, C26 and RENCA tumours. Treatment with 40 mg/kg per day sunitinib for 10 days significantly suppressed both tumour vessel density and tumour burden in all three models (Figure 5A–C), confirming the ability of sunitinib to suppress tumour angiogenesis and tumour growth in these three angiogenesis-dependent tumour models.

We then investigated the response to sunitinib in lung metastases formed by the same cell lines. Lung metastases were established by intravenous tail vein injection of 4T1, C26 or RENCA cells. In contrast to its potent activity against subcutaneously implanted tumours, the same sunitinib treatment regimen (40 mg/kg per day sunitinib for 10 days) did not significantly suppress tumour vessel density in any of the lung metastasis models (Figure 5D–F). In addition, sunitinib treatment did not reduce tumour burden in either 4T1 or C26 lung metastases (Figure 5D, E). Sunitinib treatment did significantly suppress tumour burden by ~34% in RENCA lung metastases (Figure 5F). However, this activity is modest when compared with subcutaneously implanted RENCA tumours, in which the same treatment regimen suppressed tumour burden by ~80% (Figure 5C).

Evidence that vessel co-option mediates resistance to sunitinib in 4T1 and C26 lung metastases

To determine why the lung metastases responded so poorly to this anti-angiogenic drug, we examined the histopathological growth patterns of all three lung metastasis models (Figure 6). 4T1 and C26 lung metastases had irregular margins and were highly infiltrative into the lung parenchyma (Figure 6A, E). Closer examination revealed that the cancer cells colonized the lung by growing in the alveolar air spaces and/or by growing in the alveolar walls (supplementary material, Figure S10). Staining for the pneumocyte marker CK7 revealed that the alveolar walls of the lung were clearly incorporated into the metastases (Figure 6B, F). Moreover, co-staining for CK7 and the blood vessel marker CD34 highlighted the presence of blood vessels in these tumours that were still associated with alveolar epithelial cells, showing that these tumours incorporate alveolar capillaries (Figure 6C, G). Therefore, the 4T1 and C26 models have a growth pattern that mimics the alveolar/interstitial HGP of human lung metastases, and these tumours co-opt pre-existing alveolar capillaries. Quantification of the growth pattern in 4T1 and C26 metastases revealed that this alveolar/interstitial HGP was the dominant growth pattern in both the vehicle-treated and sunitinib-treated mice (Figure 6D, H).

Our interpretation of these data is that the 4T1 and C26 models of lung metastasis co-opt pre-existing alveolar capillaries, and that these co-opted vessels are not sensitive to sunitinib treatment. These data provide a potential mechanistic explanation for the inability of sunitinib to control tumour burden in these lung metastasis models.

Evidence that a switch from angiogenesis to vessel co-option mediates resistance to sunitinib in RENCA lung metastases

The situation was more complex for RENCA lung metastases, which presented with a mixture of pushing HGP metastases (Figure 6I–K) and alveolar/interstitial HGP metastases (Figure 6L–N). In vehicle-treated mice, the pushing HGP was the prevalent growth pattern of RENCA lung metastases (Figure 6O). These pushing HGP metastases had a strikingly spherical or ‘cannonball’ shape (Figure 6I), and, instead of invading the lung parenchyma, these tumours pushed the alveolar walls away (Figure 6J). The blood vessels in pushing HGP metastases were not associated with CK7-positive pneumocytes, suggesting that these tumours vascularize through angiogenesis instead of vessel co-option (Figure 6K).

However, in sunitinib-treated mice, the alveolar/interstitial HGP was the prevalent growth pattern of RENCA lung metastases (Figure 6O). RENCA lung metastases with an alveolar/interstitial HGP had an irregular margin and infiltrated the lung parenchyma (Figure 6L). Staining for CK7 revealed incorporation of alveolar walls into the metastases (Figure 6M), and co-staining for CD34 and CK7 highlighted that these tumours incorporate pre-existing alveolar capillaries (Figure 6N).

In the analysis of vessel density in RENCA lung metastases described above (Figure 5F), vessel density was quantified across the entire tissue section without regard to the growth pattern. We therefore re-examined vessel density in RENCA lung metastases by quantifying, separately, the vessel density in pushing HGP lesions and the vessel density in alveolar/interstitial HGP lesions. Importantly, whereas vessel density was significantly lower in pushing HGP RENCA lesions from sunitinib-treated mice than in the vehicle group (supplementary material, Figure S11A–C), no significant difference in vessel density was observed between alveolar/interstitial HGP RENCA lesions from sunitinib-treated mice and the vehicle group (supplementary material, Figure S11D–F).

Our interpretation of these data is that: [1] the vessels of angiogenic pushing growth pattern RENCA lung metastases are sensitive to sunitinib; and [2] sunitinib also induces a rapid shift in growth pattern to the alveolar/interstitial HGP, which permits the co-option of alveolar capillaries that are resistant to sunitinib. This provides a potential mechanistic explanation for why
Figure 5. Limited efficacy of sunitinib in lung metastasis models as compared with subcutaneously implanted tumours. (A–C) The efficacy of sunitinib was tested in mice injected subcutaneously with 4T1 (A), C26 (B) or RENCA (C) cells. The graphs show tumour vessel density ± standard error of the mean (SEM) (left) or tumour burden ± SEM (right) in subcutaneous 4T1 (A), C26 (B) or RENCA (C) tumours after 10 days of treatment with either 40 mg/kg per day sunitinib or vehicle alone. *n* = 10 mice per experimental group for tumour burden graphs. *n* = 6 mice per experimental group for tumour vessel density graphs. (D–F) Mice were injected via the tail vein with 4T1 (D), C26 (E) or RENCA (F) cells. The graphs show tumour vessel density ± SEM (left) or tumour burden ± SEM (right) in the lungs after 10 days of treatment with either 40 mg/kg per day sunitinib or vehicle alone. *n* = 9 or 10 mice per experimental group for tumour burden graphs. *n* = 5 mice per experimental group for tumour vessel density graphs. ns, no significant difference; sun, sunitinib; veh, vehicle.

sunitinib has only a modest effect on tumour burden in the RENCA lung metastasis model.

Discussion

Here, we examined the mechanisms of tumour vascularization in human lung metastases. We report three distinct growth patterns of human lung metastases in which, if our interpretation of the histology is correct, the co-option of pre-existing vessels occurs via three distinct mechanisms. In the alveolar HGP, cancer cells invade the alveolar air spaces, which facilitates the co-option of the alveolar capillaries that lie within the incorporated alveolar walls. In the interstitial HGP, cancer cells infiltrate the alveolar walls, which again allows the co-option of alveolar capillaries, albeit via a mechanism that is distinct from that in the alveolar HGP. In the perivascular cuffing HGP, cancer cells grow as a cuff around large pre-existing vessels of the lung, resulting in the co-option of these larger vessels. We also report a pushing HGP in which the lung metastases present with a chaotically organized vasculature that is typical of tumour angiogenesis. Our interpretation of these data is that lung metastases can vascularize by co-opting pre-existing vessels of the lung (via three distinct mechanisms) or can utilize angiogenesis. Moreover, rather than being a rare event, we found that vessel co-option occurs frequently in human lung metastases.

We do acknowledge, however, that both angiogenesis and vessel co-option can occur within the same lesion. In support of this, we observed here that lung metastases can present with a mixture of growth patterns e.g. lesions in which the pushing HGP and the alveolar HGP
were both present, but in different areas of the same lesion. Moreover, in both the alveolar HGP and the interstitial HGP, it is possible that new vessels can sprout from co-opted vessels once the co-opted vessels are in the centre of the metastasis. In support of this, studies on NSCLC have shown that many of these tumours can invade the alveolar air spaces at the tumour periphery (permitting vessel co-option), but that a switch to angiogenesis then occurs in the centre of the tumour [8,9]. Presumably, this occurs because vessels co-opted at the periphery are induced to undergo angiogenesis when they find themselves within the centre of the tumour. We therefore propose that there is both spatial heterogeneity and temporal heterogeneity in the vascularization mechanisms used by human tumours, with lesions being able to utilize either angiogenesis or vessel co-option or both.

It is not currently clear why cancer cells utilize vessel co-option instead of, or as well as, activating angiogenesis when they metastasize to the lung. Previous work has suggested that, although micrometastases can rely on vessel co-option, tumours must switch to a reliance on angiogenesis as they become larger [30]. However, in the current study, we observed vessel co-option even in human lung metastases that were large (≥1 cm in diameter). If we interpret these data correctly, we must conclude that vessel co-option can be a mechanism of tumour vascularization in both micrometastases and macrometastases. In addition, our data suggest that tumours of diverse primary origin (i.e. breast, bowel, and kidney) can all utilize vessel co-option when they metastasize to lung. Given this evidence, it seems probable that the environment of the lung plays an active role in inducing cancer cells to utilize vessel co-option instead of angiogenesis.

We also provide evidence that vessel co-option mediates intrinsic resistance to anti-angiogenic therapy in preclinical lung metastasis models. Whereas the anti-angiogenic drug sunitinib suppressed the growth
of angiogenesis-dependent subcutaneously implanted 4T1 and C26 tumours, the lung metastases of 4T1 and C26 tumours utilized vessel co-option and showed intrinsic resistance to this same anti-angiogenic drug. Further evidence that vessel co-option mediates intrinsic resistance to anti-angiogenic therapy comes from a spontaneous breast cancer metastasis model using the highly metastatic MDA-MB-231LM2–4 breast cancer cell line. We reported previously that, whereas the growth of MDA-MB-231LM2–4 tumours is significantly suppressed by sunitinib when these cells are implanted orthotopically in the mammary fat pad, administration of sunitinib does not prolong the survival of mice bearing spontaneous MDA-MB-231LM2–4 metastases [31]. Importantly, we found that, whereas mammary fat pad-implanted MDA-MB-231LM2–4 tumours are angiogenic, spontaneous MDA-MB-231LM2–4 lung metastases utilize vessel co-option (Harold Dvorak and Robert Kerbel, unpublished observation). In confirmation of this, staining for CK7 and CD34 in spontaneous MDA-MB-231LM2–4 lung metastases demonstrated that these tumours have an alveolar HGP and that they do co-opt alveolar capillaries (supplementary material, figure S12). If our interpretation of these data is correct, vessel co-option is therefore associated with intrinsic resistance to sunitinib, not just in intravenous models of lung metastasis (i.e. 4T1 and C26), but also in a model of spontaneous breast cancer lung metastasis using a human breast cancer cell line (i.e. MDA-MB-231LM2–4).

Vessel co-option might also mediate acquired resistance to anti-angiogenic therapy. Although RENCA lung metastases presented mainly as angiogenic pushing HGP lesions in vehicle-treated mice, sunitinib induced a switch to an alveolar/interstitial HGP that vascularizes by vessel co-option. Importantly, whereas the vessels of pushing HGP metastases were sensitive to sunitinib, the vessels of alveolar/interstitial HGP lung metastases were not. Our interpretation of these data is that a treatment-induced switch from angiogenesis to vessel co-option could drive acquired resistance to anti-angiogenic therapy. In further support of this, Kuczynski et al. recently showed that a switch from angiogenesis to vessel co-option drives acquired resistance to the anti-angiogenic drug sorafenib in hepatocellular carcinoma [20]. Moreover, a switch from angiogenesis to vessel co-option has been reported to occur in some brain malignancies treated with anti-angiogenic therapy [17–19,23,24].

Four phase 3 trials have tested sunitinib in metastatic breast cancer, with no benefit in either progression-free survival (PFS) or overall survival (OS) being demonstrated for sunitinib [32–35]. If the quantification of vessel co-option in human breast cancer lung metastases presented here is representative of breast cancer patients as a whole, many patients entering these trials will have presented with breast cancer metastases to the lung that vascularize through vessel co-option. In addition, vessel co-option occurs in breast cancer metastases to the skin [36], lymph nodes [21,37], liver [22,38], and brain [39–41]. Therefore, vessel co-option may help to explain, at least in part, why anti-angiogenic therapy has been a disappointing therapeutic approach in metastatic breast cancer.

In contrast to its effect on breast cancer, sunitinib extends both PFS and OS in metastatic renal cancer [42,43]. Here, we found that vessel co-option occurs less frequently in human renal cancer lung metastases than in human breast cancer lung metastases. This disparity may help to explain why sunitinib is a clinically more effective treatment for metastatic renal cancer than for metastatic breast cancer. Nonetheless, both intrinsic and acquired resistance to anti-angiogenic drugs occur in renal cancer patients [44,45]. Moreover, despite showing activity in the advanced disease setting, sunitinib did not prolong disease-free survival in renal cancer patients who received this drug as adjuvant therapy [46]. We propose that vessel co-option may help to explain resistance to anti-angiogenic therapy of renal cancer in both the metastatic setting and the adjuvant setting.

In conclusion, if we have interpreted our data correctly, vessel co-option is a common event in human lung metastases that occurs via three distinct mechanisms. Moreover, our data suggest that vessel co-option may drive resistance to anti-angiogenic therapy in preclinical lung metastasis models. One limitation of our study is that, owing to a lack of sufficient lung metastasis samples from patients treated with anti-angiogenic therapy, we have not been able to examine whether there is an association between vessel co-option and resistance to anti-angiogenic therapy in patients. There are, however, clinical data showing that co-option of the pre-existing vasculature is associated with resistance to anti-angiogenic therapy in both lymph node metastases [21] and liver metastases [22]. Further research is therefore now warranted to confirm the role of vessel co-option in resistance to anti-angiogenic therapy in patients with lung metastases.

If vessel co-option does prove to be a common mechanism of resistance to anti-angiogenic therapy across multiple metastatic sites, then therapeutic approaches that can inhibit both angiogenesis and vessel co-option may be warranted for the treatment of metastatic disease. However, further research will now be required to establish how both modalities of tumour vascularization can be effectively targeted simultaneously in patients.

Author contributions statement
The authors contributed in the following way: VLB, PBV, SF, FD, EK, MRN, EW, SF, ARR: performed the experiments, collected the data, and analysed the data; VLB, PBV, AB, TS, BH, KH, FR, BD, ARR: organized the collection of tissue samples and the associated clinical data; PBV, EAK, NSV, JL, MG, HDF, SP, RSK, BD: assisted with interpretation of the data and provided critical comments on the manuscript; VLB, PBV, SP, BD, ARR: conceived of and designed the study. VLB, ARR: prepared the figures and wrote the manuscript. All authors gave final approval to the submitted version of the paper.
Acknowledgements

ARR acknowledges funding from Breakthrough Breast Cancer (recently merged with Breast Cancer Campaign forming Breast Cancer Now) and NHS funding to the NIHR Biomedical Research Centre at RM/ICR. BD was supported by a Hungarian Scientific Research Fund (SNN114490, K109626, K108465), a Semmelweis University Start-Up grant (40148–11658), ÖNB Jubiläumsfondsprojekt No. 14043, and the Vienna Fund for Innovative Interdisciplinary Cancer Research. We thank the staff of the Biological Services Unit at the ICR and the staff of the Breast Cancer Now Histopathology Core Facility for technical assistance.

References

1. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev 2008; 8: 592–603.
2. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210–221.
3. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298–307.
4. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev 2012; 12: 699–709.
5. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014; 17: 471–494.
6. Dome B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007; 170: 1–15.
7. Donnem T, Hu J, Ferguson M, et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med 2013; 2: 427–436.
8. Pezzella F, Pastorino U, Tagliabue E, et al. Neo-angiogenesis in non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151: 1417–1423.
9. Passalidou E, Trivella M, Singh N, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002; 86: 244–249.
10. Adighibe O, Micklem K, Campo L, et al. Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions. Br J Cancer 2006; 94: 1176–1179.
11. Sardari Nia P, Colpaert C, Vermeulen P, et al. Different growth patterns of non-small cell lung cancer represent distinct biologic subtypes. Ann Thorac Surg 2008; 85: 395–405.
12. Yousem SA. Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling. Hum Pathol 2009; 40: 861–867.
13. Pezzella F, Di Bacco A, Andreola S, et al. Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer 1996; 32A: 2494–2500.
14. Sardari Nia P, Hendriks J, Friedel G, et al. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma. Histopathology 2007; 51: 354–361.
15. Breast Cancer Progression Working Party. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Lancet 2000; 355: 1787–1788.
16. Szabo V, Bugayik E, Dezso K, et al. Mechanism of tumour vascularization in experimental lung metastases. J Pathol 2015; 235: 384–396.
17. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010; 12: 233–242.
18. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306–314.
19. di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of ‘rebound’ revascularization as mode of escape. Cancer Res 2011; 71: 19–28.
20. Kuzyczynska EA, Yin M, Bar-Zion A, et al. Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J Natl Cancer Inst 2016; 108: djv030.
21. Jeong HS, Jones D, Liao S, et al. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J Natl Cancer Inst 2015; 107: djv155.
22. Frentzas S, Simonoea E, Bridgeoman VL, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med 2016; 22: 1294–1302.
23. Kusters B, Leenders WP, Wesseling P, et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002; 62: 341–345.
24. Leenders WP, Kusters B, Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004; 10: 6222–6230.
25. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206–2223.
26. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unbrigaded version). Arch Pathol Lab Med 2010; 134: e48–72.
27. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3907–4013.
28. Broers JL, de Leij L, Rot MK, et al. Expression of intermediate filament proteins in fetal and adult human lung tissues. Differentiation 1989; 40: 119–128.
29. Stahlman MT, Gray ME, Whissett JA. Expression of thyroid transcription factor-1 (TTF-1) in fetal and neonatal human lung. J Histochim Cytochem 1996; 44: 673–678.
30. Holash J, Maisonnierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994–1998.
31. Guerin E, Man S, Xu P, et al. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 2013; 73: 2743–2748.
32. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capcitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121–131.
33. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11: 82–92.
34. Bergh J, Bondarenko IM, Liahimur MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012; 30: 921–929.
35. Crown JP, Dieras V, Staroslawka E, et al. Phase III trial of sunitinib in combination with capcitabine versus capcitabine monotherapy
for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013; 31: 2870–2878.

36. Colpaert CG, Vermeulen PB, Van Beest P, et al. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology 2003; 42: 530–540.

37. Naresh KN, Nerurkar AY, Borges AM. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology 2001; 38: 466–470.

38. Stessels F, Van den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 2004; 90: 1429–1436.

39. Carbonell WS, Ansorge O, Sibson N, et al. The vascular basement membrane as ‘soil’ in brain metastasis. PLoS One 2009; 4: e5857.

40. Bugyik E, Dezso K, Reiniger L, et al. Lack of angiogenesis in experimental brain metastases. J Neuropathol Exp Neurol 2011; 70: 979–991.

41. Valiente M, Obenauf AC, Jin X, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014; 156: 1002–1016.

42. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–124.

43. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584–3590.

44. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992–1000.

45. Vasudev NS, Goh V, Juttla JK, et al. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. Br J Cancer 2013; 109: 1230–1242.

46. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387: 2008–2016.

SUPPLEMENTARY MATERIAL ONLINE

Supplementary materials and methods

Supplementary figure legends

Figure S1. Consort diagram for breast cancer lung metastasis cases.

Figure S2. Consort diagram for colorectal cancer lung metastasis cases.

Figure S3. Consort diagram for renal cancer lung metastasis cases.

Figure S4. Alveolar HGP and pushing HGP of colorectal cancer lung metastases.

Figure S5. Alveolar HGP and pushing HGP of renal cancer lung metastases.

Figure S6. Examples of co-opted alveolar capillaries in human lung metastases.

Figure S7. Pattern of pneumocyte staining in the alveolar HGP.

Figure S8. Vessel co-option in the perivascular cuffing growth pattern of human lung metastases.

Figure S9. Cases of breast cancer lung metastases grouped by intrinsic molecular subtype.

Figure S10. High power views of alveolar growth pattern and interstitial growth pattern in preclinical lung metastasis models.

Figure S11. Contrasting effect of sunitinib in RENCA lung metastases with different HGPs.

Figure S12. Vessel co-option in spontaneous MDA-MB-231LM2–4 lung metastases.

Table S1. Clinical characteristics of breast cancer patients.

Table S2. Clinical characteristics of colorectal cancer patients.

Table S3. Clinical characteristics of renal cancer patients.